...are comming through.Had this sort of situation occured with sar-the share price would shift bya 0.5p upwards by now.700k at 0.48p/share is a fantastic buy as in a few weeks the investor will double his/her money at least.Stach.
It crossed my mind yesterday that why would they obtain a specific patent in australia when they already have global ip protection,maybe a clue that they are working on getting it developed into the huge markets in asia ? i thought that was an interesting development.
Apparently Guru discussed the news flow with the VAL representatives last night and explained many PI's frustrations. They took his feedback and suggestion of pulling together all this info into one, with it also being a bit less 'clinical' and that it could be understood by the masses. Whether they do this remains to be seen, but from all accounts they were understanding.
Seems that last night may well have turned out to be quite useful for us long term holders
the bio markers issue was explained to me by satu when she called me at home ie they have to get very specific patients that match the bio markers requirements so there is last chance of failure as the treatment wont be suitable for all patients but a certain group with prostrate canceretc she covers this point in one of stockcube interviews
Thanks for info and Guru also. You're doing a great job of keeping this board alive. Some posters only come when they smell something, as soon as nothing happen the next day then they just disappeared again.
Dr Satu Vainikka, CEO of ValiRx (LON:VAL), tells Proactiveinvestors that good clinical progress is being made with VAL201, the company's prostate cancer drug. The company's cash position is good, and the board has been strengthened by the recent appointment of some heavy hitters in in the pharmaceutical world. Satu says the association with specialists in the area of drug development has helped considerably in taking its drug portfolio on into the clinical phase, while the presence on the board of respected industry professionals strengthens the company's proposition when it goes to talk to the big beasts of the sector, many of which are cutting back on research & development. "Big pharma is very desperate a pipeline of new development; new drugs, new therapeutic treatment," Satu notes.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.